Staphylococcal Bacteremia and Endocarditis
Research on Staphylococcus aureus bloodstream infections including right-sided infective endocarditis. Includes MRSA and MSSA bacteremia treatment and outcomes.
Quick Answer
What it is
Research on Staphylococcus aureus bloodstream infections including right-sided infective endocarditis. Includes MRSA and MSSA bacteremia treatment and outcomes.
Key findings
- Grade A: Bacteremia/Endocarditis Cure (Daptomycin (Cubicin))
- Grade A: Nephrotoxicity vs Standard Therapy (Daptomycin (Cubicin))
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts
Quick Facts: Staphylococcal Bacteremia and Endocarditis
- Supplements Studied:1
1 supps · 2 outcomes
Detailed Outcomes
A
Bacteremia/Endocarditis Cure
Fowler NEJM 2006 (n=246): Treatment success at 42 days 44.2% vs 41.7% standard therapy (noninferiority met). 6 mg/kg IV daily. Effective for both MRSA and MSSA right-sided endocarditis. CAMERA2 trial: Adding beta-lactam did not improve outcomes vs daptomycin alone.
none
A
Nephrotoxicity vs Standard Therapy
Fowler NEJM 2006: Clinically significant renal dysfunction 11.0% daptomycin vs 26.3% standard therapy (vancomycin+gentamicin), P=0.004. Significant renal-sparing advantage. Does not require renal dose adjustment until CrCl <30 mL/min.
large↓Improves